Bio-Technology General Corp. announced Thursday that itsrecombinant human growth hormone has been grantedmarketing approval in the United Kingdom for the treatment ofshort stature. The drug has also been approved in Denmark,Luxembourg, the Netherlands, Spain and Italy. It will bemarketed in Europe by SmithKline Beecham Pharmaceuticalsunder the name Eskatrope. BTGC shares (NASDAQ:BTGC) closedThursday at $10.75, down 13 cents.
(c) 1997 American Health Consultants. All rights reserved.